Dr Reddy’s to Launch Generic Ozempic in India at Half the Price
Dr Reddy’s Laboratories is preparing to launch India’s first generic version of the popular diabetes and weight-loss drug semaglutide (Ozempic) in the coming weeks, potentially at half the price of the original.
Key Details
- Price: Expected at ₹8,000-₹9,000 for a pack of four pens, compared to Novo Nordisk’s ₹16,000.
- Approval: The Drug Controller General of India (DCGI) has already granted approval.
- Impact: Aims to improve affordability, accessibility, and ease the global supply shortage in India.
What is Semaglutide?
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It is a once-weekly injectable medication primarily for type 2 diabetes, also widely used off-label for weight management. High global demand has led to significant shortages.
Market Significance
The entry of a major domestic player like Dr Reddy’s with a generic version is a landmark for the Indian pharma sector. It is expected to increase competition, potentially lowering prices for similar drugs, and make this effective treatment more accessible to a larger patient population.
The company, a leading Indian pharmaceutical firm and major generic drug exporter, declined to comment on the development.
